HemaSphere (Aug 2023)
P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
- Manisha Bhutani,
- Alfred Garfall,
- Katarina Uttervall,
- Saad Z Usmani,
- Lionel Karlin,
- Lotfi Benboubker,
- Hareth Nahi,
- Jesús San Miguel,
- Danielle Trancucci,
- Keqin Qi,
- Tara Stephenson,
- Alfredo Perales-Puchalt,
- Katherine Chastain,
- Ajai Chari
Affiliations
- Manisha Bhutani
- 1 Levine Cancer Institute/Atrium Health, Charlotte, United States
- Alfred Garfall
- 2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
- Katarina Uttervall
- 3 Karolinska University Hospital, Stockholm, Sweden
- Saad Z Usmani
- 4 Memorial Sloan Kettering Cancer Center, New York, United States
- Lionel Karlin
- 5 Centre Hospitalier Lyon Sud, Pierre-Bénite, France
- Lotfi Benboubker
- 6 Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours, France
- Hareth Nahi
- 7 Karolinska University Hospital at Huddinge, Stockholm, Sweden
- Jesús San Miguel
- 8 University of Navarra, Pamplona, Spain
- Danielle Trancucci
- 9 Janssen Research & Development, Raritan, United States
- Keqin Qi
- 10 Janssen Research & Development, Titusville, United States
- Tara Stephenson
- 11 Janssen Research & Development, Spring House, United States
- Alfredo Perales-Puchalt
- 11 Janssen Research & Development, Spring House, United States
- Katherine Chastain
- 9 Janssen Research & Development, Raritan, United States
- Ajai Chari
- 12 Mount Sinai School of Medicine, New York, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000970428.90600.b0
- Journal volume & issue
-
Vol. 7
p. e90600b0
Abstract
No abstracts available.